<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04738396</url>
  </required_header>
  <id_info>
    <org_study_id>aLBBAP study</org_study_id>
    <nct_id>NCT04738396</nct_id>
  </id_info>
  <brief_title>Electrogram and Hemodynamic Characteristics of Adaptive LBBAP in Patients With Heart Failure or Bradycardia</brief_title>
  <official_title>Electrogram and Hemodynamic Characteristics of Adaptive LBBAP in Patients With Heart Failure or Bradycardia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-site, non-randomized, data collection study. The purpose of this study is to&#xD;
      investigate the cardiac electrical and mechanical function during LBBAP with different AV&#xD;
      intervals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Left bundle branch pacing (LBBP), achieved via trans-septal approach with the pacing tip at&#xD;
      the left side of the ventricular septum, has recently initiated and been well practiced in&#xD;
      China. LBBP is characterized with relatively ease of implantation (usually &lt;5 minutes&#xD;
      fluoroscopic use time), narrow paced QRS duration (similar to physiological pacing), low and&#xD;
      stable pacing threshold (usually around 0.5V @0.5ms, good for device longevity and long-term&#xD;
      stability without need of back-up pacing lead), high R wave amplitude for pacing management,&#xD;
      and LBBB (left bundle branch block) correction by a low pacing output.&#xD;
&#xD;
      LBBAP (left bundle branch area pacing) can generate a relatively narrow QRSd and fast left&#xD;
      ventricular activation. As AV interval is an important pacing parameter relevant to cardiac&#xD;
      function. This study is to investigate the cardiac electrical and mechanical function during&#xD;
      LBBAP with different AV intervals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ECG QRS duration</measure>
    <time_frame>At least 3 months post implant</time_frame>
    <description>The primary endpoint is QRS duration during LBBP</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cardiac Pacing</condition>
  <condition>Pacing Therapy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who received LBBAP for at least 3 months and come back to hospital for regular&#xD;
        follow-up will be considered to be recruited voluntarily.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged from 18 to 80 years old&#xD;
&#xD;
          -  Patients who are willing to provide Informed Consent&#xD;
&#xD;
          -  Patients who received LBBAP for at least 3 months&#xD;
&#xD;
          -  Patients' implanted device can provide intracardiac electrograms&#xD;
&#xD;
          -  Bradycardia patients with AVB or heart failure patients with LBBB&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are pregnant or have a plan for pregnancy during the study&#xD;
&#xD;
          -  Patients with persistent AF&#xD;
&#xD;
          -  Patients who have medical conditions that would limit study participation&#xD;
&#xD;
          -  Patients who were already enrolled in other clinical trial which would impact his/her&#xD;
             participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaohong Zhou</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shirley Zhang</last_name>
    <phone>86-21-33238535</phone>
    <email>shirley.zhang80@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ke-ping Chen</last_name>
      <phone>86-10-68314466</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruo-gu Li</last_name>
      <phone>86-21-62821990</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Greentown Cardiovascular Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>0571</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lang He</last_name>
      <phone>86-571-88857888</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

